Clinical trials: Patients With Heart Failure and Preserved Ejection Fraction - HFpEF
Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke)
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion
Background: Atrial fibrillation (AF) is the most common heart rhythm disorder worldwide. Globally, there are 37.5 million people with AF.
- Conditions
- Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke), Atrial Fibrillation New Onset, Non Valvular Atrial Fibrillation
- Trial name
- BIO-AF (NCT06949319)
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Nedim Tojaga
Heart Failure, Diastolic, Heart Failure, Systolic
Network Medicine Approaches to Classify Heart Failure With PReserved Ejection Fraction by Signatures of DNA Methylation and Point-of-carE Risk calculaTors (PRESMET)
Heart failure (HF) is a syndrome, resulting from structural or functional impairment of ventricular filling or ejection of blood.
- Conditions
- Heart Failure, Diastolic, Heart Failure, Systolic, Pulmonary Hypertension, Atrial Fibrillation
- Trial name
- PRESMET (NCT05475028)
- Testing
- RRBS
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Campania Luigi Vanvitelli
Heart Failure With Preserved Ejection Fraction (HFPEF), Renal Dysfunction
Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR
Heart failure (HF) in patients at risk is often overlooked, and when detected, there is a lack of early and effective preventive interventions.
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFPEF), Renal Dysfunction, Stage B Heart Failure
- Trial name
- WE-CARE-HF-CMR (NCT07185100)
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- German Heart Institute
Heart Failure With Preserved Ejection Fraction (HFpEF)
An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.
This study evaluated the safety and tolerability of LCZ696 treatment in Japanese heart failure patients (NYHA Class II-IV) with preserved ejection fraction after CLCZ696D2301 (PARAGON-HF).
- Trial name
- NCT03909295
- Testing
- LCZ696
- Where
- 17 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Diastolic, Multicenter Study
Diagnosis and OutcoMes evaluAtIoN of Multicenter Patients With HFpEF Using Multimodality Imaging
The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are…
- Trial name
- NCT04602338
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Heart Failure With Preserved Ejection Fraction (HFPEF)
Effects of a Multicomponent Training Program on Cardiac Function, Skeletal Muscle Metabolism, Functional Capacity, and Quality of Life in Patients With HFpEF: SENSORFIT-4HEART Study
Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome with increasing incidence and poor prognosis, accounting for up to 50% of heart failure cases.
- Trial name
- SENSORFIT-4HEA (NCT07251361)
- Testing
- Supervised training
- Where
- Spain
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Universidad Pública de Navarra
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.
- Trial name
- NCT04847557
- Testing
- Tirzepatide
- Where
- 146 sites in United States, Argentina and 8 more
- Volunteers
- 731 people
- Sponsor
- Eli Lilly and Company
Heart Failure With Preserved Ejection Fraction
Relationship Between Ambulatory Arterial Stiffness Index and Left Ventricular Diastolic Function in Patients With HFpEF
Heart failure with preserved ejection fraction (HFpEF) was considered as a heterogeneous disease with multi-organ and multi-system design, which is related to various complications, such as hypertension, obesity and…
- Trial name
- NCT05059769
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Dongying Zhang
Diabetes Mellitus, Type 2, Heart Failure Preserved Ejection Fraction
Neuromuscular Fatigue and Exercise Capacity in Patients With Type 2 Diabetes Mellitus and HFpEF
An important feature of patients with HFpEF is impaired exercise tolerance, resulting in worsening and reduced quality of life. Studies in the literature on patients with HFpEF suggest that the limited transport of oxygen to the…
- Trial name
- NCT06057623
- Testing
- Evaluation of central and peripheral neuromuscular fatigue
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Heart Failure, Preserved Ejection Fraction
Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection Fraction
The main objective of the study is to describe the effectiveness and safety outcomes among Chinese hospitalized heart failure with preserved ejection fraction (HFpEF) patients initiating Jardiance® in the real-world setting.
- Trial name
- NCT07047508
- Volunteers
- 3,000 people
- Sponsor
- Boehringer Ingelheim
Heart Failure With Preserved Ejection Fraction (HFPEF)
Mangafodipir - an Intracellular Contrast Agent for Magnetic Resonance Imaging (MRI): Measuring Manganese Uptake Rate in Heart Failure Patients With Preserved Ejection Fraction (HFpEF) Patients.
More than half of heart failure patients have preserved ejection fraction (HFpEF), a condition caused by increased wall stiffness that impairs proper heart filling.
- Trial name
- NCT06731738
- Testing
- Gadoteric acid, Mangafodipir trisodium injection
- Where
- Norway
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- IC TARGETS AS
Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF)
Colchicine in Patients With Heart Failure With Preserved Ejection Fraction and Inflammation
The main purpose of the CHIPS trial is to evaluate the efficacy and safety of colchicine in heart failure with preserved ejection fraction (HFpEF) patients with inflammation, including the effects of colchicine on circulating…
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction (HFPEF), Chronic Inflammation, Inflammation
- Trial name
- CHIPS (NCT06604611)
- Testing
- Colchicine 0.5 MG Oral Tablet Once Daily
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Dongying Zhang
Combined Pre- and Post-capillary Pulmonary Hypertension, CpcPH
Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)
This clinical trial will evaluate whether combination therapy with Dapagliflozin + Macitentan improves outcomes compared to Dapagliflozin + placebo in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH).
- Conditions
- Combined Pre- and Post-capillary Pulmonary Hypertension, CpcPH, HFmrEF, HFpEF
- Trial name
- NCT07147114
- Testing
- Combination therapy, Monotherapy
- Where
- 15 sites in South Korea
- Volunteers
- 64 people
- Sponsor
- Gachon University Gil Medical Center
Heart Failure, Diastolic
Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
Heart Failure with preserved Ejection Fraction (HFPEF) accounts for 40-50% of all heart failure patients with a frequency of hospital admissions for acute decompensation and short and long term mortality similar to patients with…
- Trial name
- ROPA-DOP (NCT01901809)
- Testing
- Furosemide, Dopamine
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Johns Hopkins University
MASH - Metabolic Dysfunction-Associated Steatohepatitis, Heart Failure With Preserved Ejection Fraction (HFPEF)
Resmetirom in Patients With MASH and HFpEF
This Phase 1b multicenter randomized double-blind placebo-controlled study evaluates the safety, tolerability and hepatic pharmacodynamic effects of resmetirom in adults with metabolic dysfunction-associated steatohepatitis…
- Trial name
- NCT07830758
- Testing
- Resmetirom
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Heart Failure
Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.
A randomized, double-blind, placebo-controlled, parallel group, multicentre study in patients with Heart Failure with preserved Ejection Fraction (HFpEF). The study will be conducted at approximately 15 sites in 5 countries.
- Trial name
- SATELLITE (NCT03756285)
- Testing
- AZD4831
- Where
- 13 sites in United States, Denmark and 3 more
- Volunteers
- 41 people
- Sponsor
- AstraZeneca
Cardiac Amyloidosis, Heart Failure With Preserved Ejection Fraction
Cardiac Amyloidosis in HFpEF Tunisian Patients
Cardiac amyloidosis (CA) has recently been reported as a common cause of heart failure with preserved left ventricular ejection fraction (HFpEF), with a prevalence of 6% in elderly HFpEF patients.
- Conditions
- Cardiac Amyloidosis, Heart Failure With Preserved Ejection Fraction, Echocardiography, CMR
- Trial name
- Amy-Card (NCT06201832)
- Where
- Tunisia
- Volunteers
- 87 people
- Sponsor
- University Tunis El Manar
Heart Failure With Preserved Ejection Fraction (HFpEF)
Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition
The correlation of coronary microvascular function and body composition with cardiopulmonary exercise capacity will be assessed in patients with heart failure with preserved ejection fraction.
- Trial name
- NCT04822649
- Testing
- Adenosine stress echocardiography with the evaluation of coronary artery blood flow
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Korea University Anam Hospital
Heart Failure, Pulmonary Hypertension
Rivet PVS Therapy in Group 2 PH-HFpEF
This clinical investigation is a prospective, multicenter, non-randomized, open-label, Early Feasibility Study to evaluate the safety, performance, and initial clinical efficacy of the Rivet PVS therapy in patients with…
- Trial name
- NCT05205265
- Testing
- Rivet Shunt
- Where
- 3 sites in United States
- Sponsor
- NXT Biomedical
Heart Failure With Preserved Ejection Fraction
Finerenone and Cardiac Remodeling in HFpEF
This prospective randomized study aims to evaluate the efficacy of Finerenone as add-on therapy to standard of care compared to standard of care alone in preventing heart failure worsening and preserving cardiac function assessed…
- Trial name
- NCT07830940
- Testing
- Finerenone, Standard of care for HFpEF Description:
- Volunteers
- 194 people
- Sponsor
- Assiut University